Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors

Trial Profile

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs 9-ING-41 (Primary) ; Carboplatin (Primary) ; Doxorubicin (Primary) ; Gemcitabine (Primary) ; Lomustine (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Bone cancer; Cancer; Glioblastoma; Haematological malignancies; Lymphoma; Non-Hodgkin's lymphoma; Ovarian cancer; Pancreatic cancer; Renal cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Actuate Therapeutics
  • Most Recent Events

    • 07 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 27 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top